1. Scrip
  2. >>Therapy Areas

Another Early-Stage VC Win: Pliant Raises $45m For Fibrosis Startup

 
• By Mandy Jackson

As venture capital investment in biotechnology skyrockets, the amount of money that companies can raise in first-time financings also is soaring to new heights, and the fibrosis-focused startup Pliant Therapeutics Inc. with its $45m Series A round is no exception to the new biotech VC rule.

As venture capital investment in biotechnology skyrockets, the amount of money that companies can raise in first-time financings also is soaring to new heights, and the fibrosis-focused startup Pliant Therapeutics Inc. with its $45m Series A round is no exception to the new biotech VC rule.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.